Pembrolizumab Shows Superior Survival in Previously Treated Advanced NSCLC

Share this content:
Pembrolizumab showed superior overall survival benefit in previously treated patients with advanced non-small cell lung cancer.
Pembrolizumab showed superior overall survival benefit in previously treated patients with advanced non-small cell lung cancer.

Pembrolizumab showed superior overall survival benefit compared with chemotherapy in previously treated patients with advanced non-small cell lung cancer (NSCLC) whose tumors express programmed death-ligand 1 (PD-L1), findings from the KEYNOTE-010 announced in a press release by Merck have shown.1

For the pivotal phase 2/3 trial, researchers enrolled 1,034 patients with NSCLC who experienced disease progression following platinum-containing systemic therapy and whose tumors expressed PD-L1. Patients were randomly assigned to receive pembrolizumab 2 mg/kg or 10 mg/kg every 3 weeks or docetaxel 75 mg/m2 every 3 weeks.

Results showed that both the approved 2 mg/kg dose and the investigational 10 mg/kg dose were associated with longer survival compared with docetaxel. The 2 pembrolizumab doses demonstrated similar efficacy.

Pembrolizumab treatment at both doses was also associated with superior progression-free survival vs docetaxel in patients whose tumors had PD-L1 expression tumor proportion scores 50% or higher; however, there was no significant difference in progression-free survival between pembrolizumab and docetaxel in PD-L1-positive patients.

In regard to tolerability, the safety profile of pembrolizumab was similar to that observed in previously reported studies that evaluated the immunotherapy in patients with advanced NSCLC.

RELATED: Vaccine May Benefit Certain Patients With Non-Small Cell Lung Cancer

“The results from this trial provide part of a growing body of evidence supporting the potential of Keytruda [pembrolizumab] in the treatment of non-small-cell lung cancer,” said Dr. Roger Perlmutter, president, Merck Research Laboratories.

Pembrolizumab is approved at a dose of 2 mg/kg for the treatment of patients with metastatic NSCLC whose tumors express PD-L1 with disease progression on or after platinum-containing chemotherapy. It is also approved for certain patients with unresectable or metastatic melanoma.

Reference

  1. Merck's Keytruda shows superior overall survival compared to chemotherapy in patients with previously treated advanced non-small cell lung cancer whose tumors express PD-L1 [news release]. Kenilworth, NJ: Merck; October 26, 2015. http://www.mercknewsroom.com/news-release/prescription-medicine-news/mercks-keytruda-pembrolizumab-shows-superior-overall-surviva. Accessed October 27, 2015.

Related Resources

You must be a registered member of Cancer Therapy Advisor to post a comment.

Regimen and Drug Listings

GET FULL LISTINGS OF TREATMENT Regimens and Drug INFORMATION

Bone Cancer Regimens Drugs
Brain Cancer Regimens Drugs
Breast Cancer Regimens Drugs
Endocrine Cancer Regimens Drugs
Gastrointestinal Cancer Regimens Drugs
Gynecologic Cancer Regimens Drugs
Head and Neck Cancer Regimens Drugs
Hematologic Cancer Regimens Drugs
Lung Cancer Regimens Drugs
Other Cancers Regimens
Prostate Cancer Regimens Drugs
Rare Cancers Regimens
Renal Cell Carcinoma Regimens Drugs
Skin Cancer Regimens Drugs
Urologic Cancers Regimens Drugs

Sign Up for Free e-newsletters